Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ: VOR )

1.300 -0.040 (-2.99%)
Streaming Delayed Price Updated: 1:18 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
8 Analysts Have This to Say About Vor Biopharma
Via Benzinga
Vor Biopharma: Q1 Earnings Insights
Via Benzinga
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Where Vor Biopharma Stands With Analysts
Via Benzinga
Truist Securities Maintains Buy Rating for Vor Biopharma: Here's What You Need To Know
Via Benzinga
Dow Rises 50 Points; Oxford Industries Shares Plunge
U.S. stocks pared some losses toward the end of trading, with the Dow Jones and S&P 500 turning higher on Friday. The Dow traded up 0.16% to 32,156.53 while the NASDAQ fell 0.16% to 11,768.17. The S&P... 
Via Benzinga
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Near Intelligence Inc. (NASDAQ: NIR) shares climbed 53.1% to $16.50. 
Via Benzinga
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant
Via Benzinga
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Vor Biopharma
Via GlobeNewswire
Analyzing Vor Biopharma's Short Interest
Vor Biopharma's (NASDAQ:VOR) short percent of float has fallen 58.58% since its last report. The company recently reported that it has 2.53 million shares sold short, which is 5.31% of all regular... 
Via Benzinga
Dow Edges Higher; Prometheus Biosciences Shares Jump
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 0.5% on Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Drops 75 Points; Crude Oil Down 2%
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping 75 points on Wednesday. 
Via Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
From Vor Biopharma
Via GlobeNewswire
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
From Vor Biopharma
Via GlobeNewswire
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
From Vor Biopharma
Via GlobeNewswire
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
Facility to support clinical manufacturing for Vor Bio’s novel cell and genome engineering pipeline while reducing the time and cost required to manufacture its eHSC and CAR-T product candidates 
From Vor Biopharma
Via GlobeNewswire
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.